Survodutide
Also known as: BI 456906
Investigational Compound. This compound is currently in clinical development and has not received regulatory approval. No established commercial regimen exists. Consult a qualified clinician for the latest information on clinical trial availability.
Overview
Clinical Summary
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist under development by Boehringer Ingelheim. Unlike tirzepatide, which targets GLP-1 and GIP receptors, survodutide engages the glucagon receptor as its secondary target. Glucagon receptor activation promotes hepatic lipid oxidation and increases energy expenditure, providing a mechanistic rationale for efficacy in both obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Phase 2 data have demonstrated clinically significant weight loss and notable improvements in liver histology. Survodutide is currently in Phase 3 development for both obesity and MASH.
Plain Language Summary
Survodutide is an investigational medication being developed by Boehringer Ingelheim that works on two hormone pathways: GLP-1 (which reduces appetite and improves blood sugar) and glucagon (which helps the liver burn fat and increases calorie expenditure). In clinical studies, it produced significant weight loss and dramatically improved fatty liver disease. It is currently in late-stage trials for both obesity and a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). If approved, it could be the first medication targeting both conditions through glucagon activation alongside GLP-1.
Mechanism of Action
Survodutide is a peptide-based dual agonist that activates both the GLP-1 receptor and the glucagon receptor (GCGR). GLP-1R activation contributes to appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion, helping to offset the hyperglycemic effect of glucagon. GCGR activation on hepatocytes stimulates lipid oxidation and ketogenesis, reduces hepatic de novo lipogenesis, and increases energy expenditure through thermogenic mechanisms. This combination of increased energy expenditure (glucagon) and decreased energy intake (GLP-1) creates a complementary approach to weight management. The hepatic effects of glucagon agonism are particularly relevant for MASH, where excessive hepatic lipid accumulation drives inflammation and fibrosis.
Evidence Summary
A Phase 2 obesity trial (n=387) showed dose-dependent weight loss of up to 14.9% at 46 weeks, with the highest dose (4.8 mg) achieving approximately 18.7% in a subset analysis. A Phase 2b MASH trial demonstrated MASH resolution without worsening fibrosis in up to 83% of patients at the highest dose (6 mg) at 48 weeks vs 18.2% placebo, with concurrent improvement in fibrosis stage in 52.5% of treated patients vs 19.7% placebo. These results positioned survodutide among the most effective investigational agents for MASH. Phase 3 trials are underway for both obesity (SYNCHRONIZE program) and MASH. Limitations include the Phase 2 stage of data, dose-limiting GI adverse events at higher doses, and absence of long-term safety data.
Safety Profile
The safety profile in Phase 2 was consistent with the GLP-1RA class, with gastrointestinal events being the most common adverse events. Nausea, diarrhea, and vomiting were dose-dependent and led to higher discontinuation rates at higher doses. Increases in heart rate were observed. The glucagon receptor component raises theoretical concerns about hyperglycemia, though the GLP-1 agonism appears to counterbalance this risk. Small, transient increases in LDL cholesterol have been noted, likely related to glucagon-mediated hepatic lipid mobilization. No pancreatitis or thyroid C-cell tumor signals have been identified, though data are limited by the early stage of development.
Contraindications
- Personal or family history of medullary thyroid carcinoma (GLP-1RA class precaution)
- Multiple endocrine neoplasia type 2
- Known hypersensitivity to the active substance or excipients
- Pregnancy and breastfeeding (insufficient data)
Adverse Events
- Nausea (dose-dependent, most common)
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
- Transient increases in heart rate
- Small transient LDL cholesterol elevations
Interactions
- May delay absorption of oral medications due to GLP-1-mediated gastric slowing
- Caution with insulin or sulfonylureas (hypoglycemia risk)
- No formal drug interaction studies have been completed
Regulatory Notes
Survodutide is in Phase 3 clinical development under Boehringer Ingelheim. It has not received FDA or EMA approval. Phase 3 programs include SYNCHRONIZE (obesity) and trials in MASH. If approved for MASH, it would be among the first pharmacotherapies for this increasingly prevalent condition. No breakthrough therapy designation has been publicly announced.
Monitoring Considerations
Monitor hepatic function including ALT, AST, and liver fat content (if imaging is available) given the MASH indication. Standard metabolic panel, HbA1c, and lipid panel including LDL cholesterol should be tracked. Monitor GI tolerability during dose escalation. Heart rate monitoring is advisable. Thyroid monitoring per GLP-1RA class precautions.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Investigational product. Stability and handling data are not publicly available. All supply is currently through clinical trial protocols.
References
- 1RCT
Survodutide for the Treatment of Obesity: A Phase 2 Randomized Clinical Trial
Le Roux CW, Zhang S, Aronne LJ, et al. (2024). JAMA
Key findings: Phase 2 trial in 387 adults with overweight/obesity. Survodutide achieved dose-dependent weight loss of up to 14.9% at 46 weeks. The 4.8 mg dose showed 18.7% weight loss in a subset analysis. Improvements in metabolic parameters observed.
Limitations: Phase 2 study. Dose-finding design. Higher GI AE rates at higher doses.
View source - 2RCT
Survodutide for MASH: Phase 2b Randomized Clinical Trial
Sanyal AJ, Bedossa P, Engel S, et al. (2024). New England Journal of Medicine
Key findings: Phase 2b trial in patients with biopsy-confirmed MASH. Survodutide achieved MASH resolution without worsening fibrosis in up to 83% of patients at the highest dose (6 mg) at 48 weeks vs 18.2% placebo.
Limitations: Phase 2b. Biopsy-based endpoints have variability. GI tolerability was dose-limiting.
View source - 3review
Dual GLP-1/Glucagon Agonism: Translating Physiology to Therapeutics
Parker VER, Robertson D, Wang T, et al. (2020). Advances in Experimental Medicine and Biology
Key findings: Review of the pharmacological rationale for dual GLP-1/glucagon agonism. Glucagon component promotes hepatic fat oxidation and energy expenditure while GLP-1 offsets hyperglycemic risk.
Limitations: Narrative review. Published before clinical data matured.
Last reviewed: 2026-03-24 | Version: 1 | Status: Published
More in Metabolic/GLP-1
Retatrutide
LY3437943 · Reta
Retatrutide is an investigational weight loss medication that works on three different hormone pathways at once. In clinical trials, people lost an average of about 24% of their body weight over 48 weeks, which is more than currently available medications achieve. It is still being studied and has not yet been approved by the FDA.
Cagrilintide
NN9838 · AM833
Cagrilintide is an investigational medication that mimics a natural hormone called amylin, which helps you feel full after eating. It is being developed as a once-weekly injection for weight management. It is also being studied in combination with semaglutide (a GLP-1 medication) under the name CagriSema, which may produce greater weight loss than either drug alone.
CagriSema
Cagrilintide + Semaglutide · NNC9204-1706 + NNC9204-0530
CagriSema combines two medications in a single weekly injection: semaglutide (which works on the GLP-1 pathway) and cagrilintide (which works on the amylin pathway). By targeting two different hunger-related hormone systems at once, it may produce greater weight loss than either medication alone. It is currently in late-stage clinical trials.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider